KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES;한국원자력의학원
发明人:
SONG, JIE YOUNG,송지영,AHN, JI YEON,안지연,JUNG, IN SUNG,정인성,LEE, SAE LO OOM,이새로움,SON, A RANG,손애랑,NAM, KY YOUB,남기엽,CHOI, HYUN KYUNG,최현경,SEO, SEUNG YONG,서승용,YUE YUAN,원월,SONG, JIE YOUNGKR,AHN, JI YEONKR,JUNG, IN SUNGKR,LEE, SAE LO OOMKR,SON, A RANGKR,NAM, KY YOUBKR,CHOI, HYUN KYUNGKR,SEO, SEUNG YONGKR,YUE YUANCN
申请号：
KR1020140193138
公开号：
KR1020150085776A
申请日:
2014.12.30
申请国别(地区):
KR
年份:
2015
代理人:
摘要：
The present invention relates to an anti-cancer supplement agent including a benzo[d]oxazole derivative as an effective ingredient. More specifically, the benzo[d]oxazole derivative, which is a nuclear factor E2-related factor 2 (Nrf2) inhibitor, can increase production of reactive oxygen species (ROS) by activity of Nrf2 that induces an antioxidant enzyme to remove ROS that kills a cancer cell. Therefore, the benzo[d]oxazole derivative can be used as an anti-cancer supplement agent that shows therapeutic effects in anticancer agent therapy or radiation treatment, and in this regard, the benzo[d]oxazole derivative can overcome tolerance of the cancer cell to anti-cancer agent therapy or radiation treatment, and can enhance apoptotic effects on the cancer cell.본 발명은 벤조[d]옥사졸 유도체를 유효성분으로 함유하는 항암활성 보조제에 관한 것으로, 보다 상세하게는 Nrf2 (Nuclear factor E2-related factor 2)활성 억제제인 벤조[d]옥사졸 유도체는 암세포를 사멸시키는 활성산소종을 제거하는 항산화효소를 유도하는 Nrf2의 활성을 억제하여, 활성산소 발생량을 증가시킬 수 있으므로, 항암제 또는 방사선 치료에 병용하여 사용할 수 있는 항암활성 보조제로 사용하여 항암제 또는 방사선 치료에 나타나는 내성을 극복하고 암세포 사멸 효과를 증진 시킬 수 있다.
